HOMA-IR: Calculating Insulin Resistance

Fasting glucose is the number most people get tested and the number that stays normal longest. It is normal through the years when insulin resistance is developing, normal while the pancreas is quietly working harder every year to keep it that way, and abnormal only once that compensation begins to fail — often a decade or more after the process started. HOMA-IR is the arithmetic that recovers those missing years, and it requires nothing more than adding one inexpensive test to a panel you were already having.

The formula

HOMA-IR = (fasting glucose mg/dL × fasting insulin mIU/mL) / 405 (Matthews et al., Diabetologia 1985).

For SI units: HOMA-IR = (fasting glucose mmol/L × fasting insulin mU/L) / 22.5. Both produce the same scale, so a result is comparable regardless of which units the lab reported.

The constant in the denominator is not arbitrary. It normalises the product so that a healthy young adult with normal insulin sensitivity scores approximately 1.0. That is why the interpretive ranges below cluster so tightly around small numbers — the score is built to make 1.0 mean "normal".

Why multiplying the two is the whole idea

This is the part that makes HOMA-IR worth understanding rather than merely calculating.

Glucose alone tells you the outcome. Insulin alone tells you the effort. Neither is interpretable without the other, because the same glucose value means completely different things depending on how much insulin it took to produce. A person whose fasting glucose sits comfortably in range on low insulin has a healthy system. A person with the identical glucose value on high insulin has a system that is already failing and compensating — and on a standard panel the two look the same.

Multiplying them captures exactly that. The product rises when glucose rises, when insulin rises, or when both do, which corresponds to the actual natural history: insulin climbs first while glucose is held flat, then glucose begins to drift as the beta cells can no longer keep up. Long-running cohort work that tracked people for years before diagnosis shows precisely this sequence — insulin sensitivity deteriorating and insulin secretion compensating well before glycaemia moves (trajectories of glycaemia and insulin sensitivity before diabetes diagnosis, Diabetologia 2017). HOMA-IR reads the first half of that story. Fasting glucose and HbA1c read the second.

Interpreting the number

• <1.0 — optimal insulin sensitivity
• 1.0-2.0 — borderline insulin resistance
• 2.0-3.5 — insulin resistance
• >3.5 — significant insulin resistance

Note how far these sit below the point at which a standard panel would flag anything. Someone at 2.5 typically has a normal fasting glucose, a normal HbA1c and a lipid panel that raises no comment, and is several years into a process. That is the entire clinical value of the calculation: it moves the detection point earlier, into the window where the condition is still readily reversible. The gap between normal and optimal ranges is nowhere wider than it is here.

How well it actually works

The reference method for measuring insulin sensitivity is the euglycemic-hyperinsulinemic clamp: insulin is infused at a fixed rate while glucose is infused at whatever rate is needed to hold blood glucose constant, and the glucose infusion rate becomes the direct measure of sensitivity (DeFronzo et al., Am J Physiol 1979). It is accurate and it is impractical — two intravenous lines, continuous infusions, several hours, and a research setting.

HOMA-IR correlates with clamp results closely enough for clinical use at a fraction of the cost and effort (Bonora et al., Diabetes Care 2000). What it measures, strictly, is hepatic insulin sensitivity — the fasting state is dominated by the liver's glucose output and how well insulin restrains it. Muscle insulin sensitivity, which dominates after a meal, is a related but not identical thing. This is a real limitation rather than a technicality, and it is why HOMA-IR should be read alongside post-meal information rather than as a complete picture.

Where it goes wrong

Most bad HOMA-IR results are bad inputs rather than bad biology.

• Not genuinely fasted. Insulin responds to food within minutes and remains elevated for hours. A coffee with milk invalidates the result. An overnight fast, water only.
• Insulin assays vary between laboratories more than glucose assays do. Compare values from the same lab where possible; a change of platform can produce an apparent change that did not happen.
• Single values are noisy. Fasting insulin varies day to day. A borderline result is worth repeating before acting on it.
• It fails once beta cells decline. In established type 2 diabetes with falling insulin production, HOMA-IR can fall while the underlying resistance is unchanged or worse. The score is a screening and tracking tool for the compensated phase, not a diagnostic in the decompensated one.
• Acute illness, significant stress and some medications move insulin independently of chronic insulin sensitivity.

When to calculate it

• Initial metabolic evaluation, particularly with central adiposity, hypertension or a family history of type 2 diabetes
• Any normal fasting glucose that sits alongside symptoms or findings suggesting a metabolic problem
• Tracking the response to a change in diet, training or body weight
• Tracking the response to medical therapy
• PCOS evaluation, where insulin resistance is frequently the upstream driver
• Risk stratification, years before the standard thresholds would trigger

It works best as part of a small cluster rather than alone. Fasting insulin supplies half the calculation and is informative in its own right; the triglyceride-to-HDL ratio reflects the same physiology through lipids and costs nothing extra; HbA1c gives the three-month glycaemic average that HOMA-IR deliberately does not. Read together, they usually agree, and where they disagree the disagreement is informative.

Tracking it over time

HOMA-IR is among the most responsive metabolic markers available, and the reason is structural. HbA1c reflects the average glucose over roughly three months and is anchored by the lifespan of red cells, so it cannot move quickly even when the underlying physiology has. Fasting insulin has no such anchor — it reflects what the pancreas is doing this week. A person whose insulin sensitivity improves will see it in HOMA-IR while HbA1c has barely begun to shift.

Typical timelines:

• Diet and training changes move it over three to six months, with the first change often visible earlier
• Medical therapy tends to move it further, and earlier than HbA1c does
• Substantial weight loss moves it most of all

Watching the number fall across visits is one of the more concrete pieces of feedback available in metabolic medicine, and it arrives while there is still something worth preventing. What actually reverses insulin resistance covers the interventions themselves.

Bottom line

HOMA-IR multiplies fasting glucose by fasting insulin because the outcome and the effort required to produce it are only interpretable together. It detects the compensated phase of insulin resistance — the years when insulin is climbing and glucose is still normal — which is precisely the window in which the problem is most reversible and least likely to be noticed. It validates well against the research reference method, it reflects hepatic rather than muscle insulin sensitivity, and it becomes unreliable once beta-cell function declines. Order fasting insulin alongside fasting glucose, calculate it, repeat borderline values, and track the trend rather than the single number.

Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.